Investments
381Portfolio Exits
76Funds
17Partners & Customers
2About Sofinnova Partners
Sofinnova Partners is a European venture capital firm specializing in Life Sciences. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs. The company was founded in 1972 and is based in Paris, France.

Want to inform investors similar to Sofinnova Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Sofinnova Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Sofinnova Partners in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing Sofinnova Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sofinnova Partners in 2 CB Insights research briefs, most recently on Jun 16, 2022.
Latest Sofinnova Partners News
Feb 2, 2023
In detail, this new financing was led by Sofinnova Partners and co-managed by Intermediate Capital Group, but the transaction also benefited from the participation of historical investors such as Andera Partners, Novo Holdings, Kurma Partners, EQT Life Science, and the Innobio 2 fund of Bpifrance Investissement. New investors also contributed to the €130 million investment. 0 Amolyt Pharma is a Lyon-based biotech specializing in rare endocrine diseases that develops a treatment for hypoparathyroidism and acromegaly. This start-up has just completed the largest fundraising in the history of the biotech sector in France Read more about Amolyt Pharma’s latest financing round and find the most important business headlines of the day with our companion app Born2Invest. Amolyt Pharma is a biotech expert in rare diseases Founded in 2015, Amolyt Pharma specializes in treatments for rare endocrine diseases. It currently has two drug candidates: AZP-3813, for the treatment of acromegaly, and, most importantly, AZP-3601, known as eneboparatide and aimed at curing hypoparathyroidism (a rare disease causing a lack of production of parathyroid hormone, which is involved in the regulation of calcium levels). Having completed Phase 2 of the latter treatment in September with positive results on its safety and efficacy, all funding will be focused on AZP-3601. Amolyt Pharma is counting on this new round of financing to fund its phase 3. This phase will include around 100 patients and is due to start in the first half of this year. “We have the financial resources to successfully complete this stage, which should lead to a marketing application in 2025, primarily in the United States,” said Thierry Abribat, founder and CEO of Amolyt Pharma. Amolyt Pharma closes a €130 million financing round After having raised €67 million in the previous round co-led by the American Sectoral Asset Management and Andera Partners, the Lyon-based biotech company has closed a €130 million Series C round, the largest in the history of biotechs in France. In detail, this new financing was led by Sofinnova Partners and co-managed by Intermediate Capital Group, but the transaction also benefited from the participation of historical investors such as Andera Partners, Novo Holdings, Kurma Partners, EQT Life Science, and the Innobio 2 fund of Bpifrance Investissement. New investors also contributed to the €130 million investment with funds managed by Tekla Capital Investment LLC, and CTI Life Sciences. Finally, Thierry Abribat welcomed the financing: “We are very pleased to complete this important Series C financing which will allow us, on the basis of our positive clinical results with enneboparatide, to accelerate the growth of Amolyt Pharma and its portfolio at the international level”. In conclusion, this new round of financing for Amolyt Pharma will enable the Lyon-based biotech company to accelerate its growth, particularly internationally, by capitalizing on the recent success of its phase 2 treatment. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures . First published in Planete GRANDE ECOLES , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Sofinnova Partners Investments
381 Investments
Sofinnova Partners has made 381 investments. Their latest investment was in Julier Medical as part of their Seed VC on January 1, 2023.

Sofinnova Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/23/2023 | Seed VC | Julier Medical | $3.26M | Yes | 2 | |
1/6/2023 | Series C | Amolyt Pharma | $138.38M | Yes | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Santé, Sofinnova Partners, Tekla Capital Management, and Turenne Group | 7 |
12/19/2022 | Series B | EnginZyme | $22.34M | No | 16 | |
12/2/2022 | Series A | |||||
11/29/2022 | Series B |
Date | 1/23/2023 | 1/6/2023 | 12/19/2022 | 12/2/2022 | 11/29/2022 |
---|---|---|---|---|---|
Round | Seed VC | Series C | Series B | Series A | Series B |
Company | Julier Medical | Amolyt Pharma | EnginZyme | ||
Amount | $3.26M | $138.38M | $22.34M | ||
New? | Yes | Yes | No | ||
Co-Investors | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Santé, Sofinnova Partners, Tekla Capital Management, and Turenne Group | ||||
Sources | 2 | 7 | 16 |
Sofinnova Partners Portfolio Exits
76 Portfolio Exits
Sofinnova Partners has 76 portfolio exits. Their latest portfolio exit was Odoo on June 08, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/8/2022 | Shareholder Liquidity | 1 | |||
5/2/2022 | Acquired | 1 | |||
1/7/2022 | IPO | Public | 4 | ||
Date | 6/8/2022 | 5/2/2022 | 1/7/2022 | ||
---|---|---|---|---|---|
Exit | Shareholder Liquidity | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 1 | 4 |
Sofinnova Partners Acquisitions
1 Acquisition
Sofinnova Partners acquired 1 company. Their latest acquisition was NovusPharma on September 20, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/20/1999 | Convertible Note | Management Buyout | 1 |
Date | 9/20/1999 |
---|---|
Investment Stage | Convertible Note |
Companies | |
Valuation | |
Total Funding | |
Note | Management Buyout |
Sources | 1 |
Sofinnova Partners Fund History
17 Fund Histories
Sofinnova Partners has 17 funds, including Sofinnova Industrial Biotech II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/17/2021 | Sofinnova Industrial Biotech II | $169.61M | 1 | ||
10/19/2021 | Sofinnova Capital X | $549.69M | 1 | ||
7/13/2021 | MD Start III | $75M | 2 | ||
3/3/2021 | Sofinnova Crossover Fund | ||||
10/17/2019 | Sofinnova Capital IX |
Closing Date | 11/17/2021 | 10/19/2021 | 7/13/2021 | 3/3/2021 | 10/17/2019 |
---|---|---|---|---|---|
Fund | Sofinnova Industrial Biotech II | Sofinnova Capital X | MD Start III | Sofinnova Crossover Fund | Sofinnova Capital IX |
Fund Type | |||||
Status | |||||
Amount | $169.61M | $549.69M | $75M | ||
Sources | 1 | 1 | 2 |
Sofinnova Partners Partners & Customers
2 Partners and customers
Sofinnova Partners has 2 strategic partners and customers. Sofinnova Partners recently partnered with Apollo on May 5, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/16/2022 | Partner | United States | Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership . | 2 | |
2/28/2018 | Partner |
Date | 5/16/2022 | 2/28/2018 |
---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | United States | |
News Snippet | Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership . | |
Sources | 2 |
Sofinnova Partners Team
12 Team Members
Sofinnova Partners has 12 team members, including current Chief Financial Officer, Christophe Blanche.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.